{"entity":{"id":"nct07825753","kind":"trial","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","aka":["PROBE"],"tldr":"A phase 2 trial of trastuzumab emtansine, trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.","summary":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer is a phase 2, interventional study registered as NCT07825753 by Fudan University, with a registry enrolment figure of 225 participants, started 2026-09-10 and due to reach its primary completion in 2027-09-01. Interventions recorded: Trastuzumab emtansine (T-DM1); Trastuzumab deruxtecan (T-DXd); Datopotamab deruxtecan (Dato-DXd); Sacituzumab govitecan (SG); Enfortumab vedotin (EV); Becotatug vedotin (MRG003); Izalontamab brengitecan (iza-bren / BL-B01D1); Mirvetuximab soravtansine (MIRV). Conditions listed: Advanced or Metastatic Pancreatic Adenocarcinoma; Advanced or Metastatic Breast Cancer (BC). Primary outcome: Objective Response Rate (ORR) as Assessed by RECIST 1.1. Pancreatic eligibility wording from the registry: \"Histologically confirmed recurrent (unresectable) or metastatic advanced pancreatic cancer or breast cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07825753","url":"https://clinicaltrials.gov/study/NCT07825753"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-emtansine","trastuzumab-deruxtecan","datopotamab-deruxtecan","sacituzumab-govitecan","enfortumab-vedotin","izalontamab-brengitecan","mirvetuximab-soravtansine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07825753","phase":"2","setting":"An Umbrella Clinical Trial of Antibody/Peptide-Drug Conjugates Matched by Mass Spectrometry-Based Absolute Quantitation of Proteins in Locally Advanced or Metastatic Pancreatic or Breast Cancer","sponsor":"Fudan University","enrolled":225,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07825753/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}